Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. EVH
EVH logo

EVH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.090
Open
3.030
VWAP
3.01
Vol
2.34M
Mkt Cap
342.73M
Low
2.920
Amount
7.04M
EV/EBITDA(TTM)
9.82
Total Shares
111.64M
EV
1.16B
EV/OCF(TTM)
29.90
P/S(TTM)
0.19
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
Show More

Events Timeline

(ET)
2026-03-02
07:40:00
Oppenheimer Lowers Evolent Health Price Target to $6
select
2026-02-25 (ET)
2026-02-25
16:40:00
Nasdaq Rises 1.26% as Investors Await Nvidia Earnings
select
2026-02-25
12:10:00
Nasdaq Rises 1.09% as Nvidia Earnings Report Draws Attention
select
2026-02-24 (ET)
2026-02-24
16:21:00
Evolent Reports Q4 Revenue of $468.72M, Exceeds Expectations
select

News

moomoo
4.0
03-02moomoo
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
  • Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
  • Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
PRnewswire
1.0
02-26PRnewswire
Evolent Health to Participate in Investor Conferences
  • Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
  • Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
  • Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
  • Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
seekingalpha
9.5
02-25seekingalpha
Evolent Health Q4 2025 Earnings Call Insights
  • Revenue and EBITDA Performance: Evolent Health reported Q4 2025 revenue of $469 million and adjusted EBITDA of $37.8 million, both exceeding the midpoint of guidance, indicating sustained momentum in organic growth and profitability.
  • Future Growth Expectations: CEO Seth Blackley forecasts approximately 30% revenue growth in 2026, with 65% of revenue expected to come from oncology, up from 36% in 2025, highlighting a strategic shift towards high-growth areas.
  • Customer and Contract Expansion: The company migrated approximately 90% of Performance Suite revenue under a new model, retaining all key customers and signing two major new clients in the past year, enhancing market competitiveness and customer base.
  • Financial Outlook and Challenges: Despite anticipating a $40 million headwind from exchange membership declines, the company plans to achieve $2.5 billion in revenue and $125 million in adjusted EBITDA, demonstrating confidence in future growth.
seekingalpha
4.0
02-25seekingalpha
KeyBanc Downgrades Evolent Health Rating Amid EBITDA Concerns
  • Rating Downgrade: KeyBanc Capital Markets downgraded Evolent Health from overweight to sector weight due to concerns over the company's future EBITDA performance, reflecting a cautious market sentiment regarding its profitability.
  • Earnings Beat: Despite the Q4 financial results released on the same day exceeding market expectations, analyst Matthew Gillmor noted that EBITDA is expected to be heavily weighted in H2 at 70%, indicating seasonal volatility in the company's earnings.
  • Future Outlook: Gillmor also mentioned that the Street EBITDA target for 2027 is expected to be lowered to $187 million, suggesting a decline in market confidence regarding the company's long-term profitability.
  • Strong Demand: Despite the downgrade, Evolent's late-stage pipeline remains robust, and high renewal rates with existing customers reflect strong demand among health plans to control specialty costs, particularly in oncology, supporting the company's shift to the PS 2.0 model.
Benzinga
6.5
02-25Benzinga
Wall Street Analysts Adjust Ratings
  • Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions of these firms.
  • Market Reaction Insight: While specific rating changes are not detailed, analysts' opinions typically influence investor decisions, potentially leading to stock price fluctuations.
  • Investor Focus: For those considering buying FSLR stock, analysts' insights will serve as a crucial reference point, likely impacting their investment strategies.
  • Rating Change Transparency: Comprehensive information on analyst rating changes can be found on Benzinga's analyst ratings page, providing deeper market insights to assist investors in making informed decisions.
stocktwits
9.5
02-25stocktwits
Evolent Health Q4 Earnings Analysis and Outlook
  • EBITDA Guidance Downgrade: Evolent Health's forecast for 2026 EBITDA is set between $110 million and $140 million, falling short of the $151.2 million reported for FY2025, indicating challenges in profitability recovery that may impact investor confidence.
  • Q4 Revenue Performance: Evolent's Q4 revenue decreased by 27% to $468.7 million, yet it surpassed Wall Street's expectations of $467.5 million, demonstrating the company's ability to maintain market competitiveness amid adversity.
  • Rising Debt Leverage: KeyBanc projects Evolent's debt leverage to rise to approximately seven times, reflecting financial management pressures that could lead to increased future financing costs and affect overall financial health.
  • Retail Sentiment Shift: Despite a more than 5% drop in pre-market trading, retail investor sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating a reassessment of the company's future potential in the market.
Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
Wall Street analysts forecast EVH stock price to rise
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
5.00
Averages
9.33
High
16.00
Current: 0.000
sliders
Low
5.00
Averages
9.33
High
16.00
UBS
Buy -> Buy
downgrade
$10 -> $5
AI Analysis
2026-02-26
Reason
UBS
Price Target
$10 -> $5
AI Analysis
2026-02-26
downgrade
Buy -> Buy
Reason
UBS lowered the firm's price target on Evolent Health to $5 from $10 and keeps a Buy rating on the shares.
Citi
Buy -> Buy
downgrade
$6 -> $4
2026-02-26
Reason
Citi
Price Target
$6 -> $4
2026-02-26
downgrade
Buy -> Buy
Reason
Citi lowered the firm's price target on Evolent Health to $4 from $6 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EVH
Unlock Now

Valuation Metrics

The current forward P/E ratio for Evolent Health Inc (EVH.N) is 16.41, compared to its 5-year average forward P/E of 47.83. For a more detailed relative valuation and DCF analysis to assess Evolent Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
47.83
Current PE
16.41
Overvalued PE
297.45
Undervalued PE
-201.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.65
Current EV/EBITDA
9.44
Overvalued EV/EBITDA
29.42
Undervalued EV/EBITDA
11.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.41
Current PS
0.19
Overvalued PS
2.06
Undervalued PS
0.75

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

news about stocks that are below 10 dollar
Intellectia · 100 candidates
Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative
Ticker
Name
Market Cap$
top bottom
XWEL logo
XWEL
XWELL Inc
6.98M
LRMR logo
LRMR
Larimar Therapeutics Inc
494.39M
VSME logo
VSME
VS Media Holdings Ltd
5.06M
EVH logo
EVH
Evolent Health Inc
350.52M
NVTS logo
NVTS
Navitas Semiconductor Corp
2.27B
SBET logo
SBET
Sharplink Inc
1.46B
what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B
show me good penny stocks
Intellectia · 41 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
MVST logo
MVST
Microvast Holdings Inc
951.73M
EVGO logo
EVGO
EVgo Inc
951.67M
REAX logo
REAX
Real Brokerage Inc
781.54M
URG logo
URG
Ur-Energy Inc
726.09M
BTBT logo
BTBT
Bit Digital Inc
721.79M
please I only need just one penny stock 🙏
Intellectia · 125 candidates
Market Cap: <= 500.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
GEVO logo
GEVO
Gevo Inc
487.04M
CLNE logo
CLNE
Clean Energy Fuels Corp
486.85M
CERS logo
CERS
Cerus Corp
485.98M
ALT logo
ALT
Altimmune Inc
482.06M

Whales Holding EVH

C
Castle Hook Partners LP
Holding
EVH
-3.83%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Evolent Health Inc (EVH) stock price today?

The current price of EVH is 3.02 USD — it has decreased -1.63

What is Evolent Health Inc (EVH)'s business?

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

What is the price predicton of EVH Stock?

Wall Street analysts forecast EVH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVH is9.33 USD with a low forecast of 5.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evolent Health Inc (EVH)'s revenue for the last quarter?

Evolent Health Inc revenue for the last quarter amounts to 468.72M USD, decreased -27.50

What is Evolent Health Inc (EVH)'s earnings per share (EPS) for the last quarter?

Evolent Health Inc. EPS for the last quarter amounts to -3.85 USD, increased 1325.93

How many employees does Evolent Health Inc (EVH). have?

Evolent Health Inc (EVH) has 4200 emplpoyees as of March 11 2026.

What is Evolent Health Inc (EVH) market cap?

Today EVH has the market capitalization of 342.73M USD.